



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BM/BSE-NSE

Date : 09.11.2024

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--	---

Dear Sir,

**Sub : Financial Results For The Quarter And Half Year Ended 30<sup>th</sup> September, 2024**

This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended 30<sup>th</sup> September, 2024.

Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed herewith.

Kindly take the intimation on record.

Thanking you,

Yours faithfully,  
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)  
Company Secretary and Compliance Officer  
Membership No. A38972  
Encl : As above

**ZIM LABORATORIES LIMITED**

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur  
Maharashtra, India. Ph. + 91.7118.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,  
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

---

**Walker Chandiook & Co LLP**

16th Floor, Tower III,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2699  
F +91 22 6626 2601

## **Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

### **To the Board of Directors of ZIM Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **ZIM Laboratories Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended **30 September 2024** and the consolidated year to date results for the period 01 April 2024 to 30 September 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

**ZIM Laboratories Limited**

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

4. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

**KHUSHROO**  
**B PANTHAKY**

Digitally signed by  
KHUSHROO B  
PANTHAKY  
Date: 2024.11.09  
16:30:49 +05'30'

**Khushroo B. Panthaky**

Partner

Membership No:042423

**UDIN:24042423BKCMXL8847**

Place: Mumbai

Date: 09 November 2024

**ZIM Laboratories Limited**  
**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and**  
**Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations**  
**and Disclosure Requirements) Regulations, 2015 (as amended)**

---

**Annexure 1**

**List of entities included in the Statement**

**Subsidiary companies**

1. ZIM Laboratories FZE
2. ZIM Health Technologies Limited
3. SIA ZIM Laboratories Limited
4. ZIM Thinorals Private Limited
5. ZIM Laboratories Middle East DMCC (w.e.f. 28 September 2023)
6. ZIMTAS PTY Limited, Australia (w.e.f. 5 March 2024)

**KHUSHROO**  
**B PANTHAKY**

Digitally signed by  
KHUSHROO B  
PANTHAKY  
Date: 2024.11.09  
16:31:18 +05'30'



**ZIM Laboratories Limited**

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India  
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

**A. STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30 SEPTEMBER 2024**

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income</b>						
	a) Revenue from operations	9,214.33	8,182.44	8,582.61	17,396.77	15,326.90	36,742.44
	b) Other income	132.08	99.89	142.15	231.97	253.69	518.39
	<b>Total income</b>	<b>9,346.41</b>	<b>8,282.33</b>	<b>8,724.76</b>	<b>17,628.74</b>	<b>15,580.59</b>	<b>37,260.83</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	3,551.84	3,100.93	4,096.35	6,652.77	7,270.36	17,769.83
	b) Purchases of stock-in-trade	313.84	265.74	204.04	579.58	267.13	779.61
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	345.17	256.40	(308.40)	601.57	(434.05)	(1,405.32)
	d) Employee benefits	1,545.13	1,450.92	1,282.68	2,996.05	2,545.96	5,334.27
	e) Finance costs	288.75	285.85	121.69	574.60	295.11	692.44
	f) Depreciation and amortisation	500.09	494.28	408.55	994.37	811.11	1,595.18
	g) Other expenses	2,505.30	2,304.77	2,375.51	4,810.07	4,262.09	10,130.58
	<b>Total expenses</b>	<b>9,050.12</b>	<b>8,158.89</b>	<b>8,180.42</b>	<b>17,209.01</b>	<b>15,017.71</b>	<b>34,896.59</b>
3	<b>Profit before tax (1-2)</b>	<b>296.29</b>	<b>123.44</b>	<b>544.34</b>	<b>419.73</b>	<b>562.88</b>	<b>2,364.24</b>
4	<b>Tax expense</b>						
	Current Tax	24.70	27.62	84.06	52.32	87.90	94.15
	Deferred Tax	33.45	5.99	45.33	39.44	37.37	545.46
	<b>Total tax expense</b>	<b>58.15</b>	<b>33.61</b>	<b>129.39</b>	<b>91.76</b>	<b>125.27</b>	<b>639.61</b>
5	<b>Net Profit after tax (3-4)</b>	<b>238.14</b>	<b>89.83</b>	<b>414.95</b>	<b>327.97</b>	<b>437.61</b>	<b>1,724.63</b>
6	<b>Other comprehensive income - profit/(loss)</b>						
	a) Items that will not be reclassified to profit or loss	(13.47)	(13.47)	(16.29)	(26.94)	(32.57)	(53.88)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	3.92	3.92	4.74	7.84	9.48	15.69
	c) Items that may be reclassified to profit or loss	24.84	2.50	12.32	27.34	9.46	13.29
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other comprehensive income (net of tax) - profit/(loss)</b>	<b>15.29</b>	<b>(7.05)</b>	<b>0.77</b>	<b>8.24</b>	<b>(13.63)</b>	<b>(24.90)</b>
7	<b>Total comprehensive income (5+6)</b>	<b>253.43</b>	<b>82.78</b>	<b>415.72</b>	<b>336.21</b>	<b>423.98</b>	<b>1,699.73</b>
8	<b>Net Profit after tax attributable to</b>						
	Owners	238.14	89.83	414.95	327.97	437.61	1,724.64
	Non-controlling interest	-	(0.00)	-	(0.00)	-	(0.01)
9	<b>Other comprehensive Income attributable to</b>						
	Owners	15.29	(7.05)	0.77	8.24	(13.63)	(24.90)
	Non-controlling interest	-	(0.00)	-	(0.00)	-	-
10	<b>Total Comprehensive Income attributable to</b>						
	Owners	253.43	82.78	415.72	336.21	423.98	1,699.74
	Non-controlling interest	-	(0.00)	-	(0.00)	-	(0.01)
11	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
12	Other equity (revaluation reserve : Rs. Nil)						19,002.00
13	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) ( Rs. )						
	Basic	0.49	0.18	0.85	0.67	0.90	3.54
	Diluted	0.49	0.18	0.85	0.67	0.90	3.54



**B. Consolidated Balance Sheet**

	As at 30.09.2024 Rs. in lakhs (Unaudited)	As at 31.03.2024 Rs. in lakhs (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	16,440.49	15,693.35
Capital work-in-progress	3,334.70	2,351.60
Goodwill on consolidation	16.94	16.94
Other intangible assets	311.45	372.34
Intangible assets under development	2,498.18	1,876.68
Financial Assets		
Investments	5.15	5.15
Other financial assets	86.06	78.55
Non-current tax assets (net)	376.07	386.78
Other non-current assets	504.69	1,135.99
	<b>23,573.73</b>	<b>21,917.38</b>
<b>Current assets</b>		
Inventories	6,792.58	8,126.29
Financial Assets		
Trade receivables	8,158.81	10,016.54
Cash and cash equivalents	507.50	960.02
Bank balances other than cash and cash equivalents	73.95	86.38
Other financial assets	20.07	31.85
Other current assets	3,609.00	3,543.77
	<b>19,161.91</b>	<b>22,764.85</b>
<b>TOTAL ASSETS</b>	<b>42,735.64</b>	<b>44,682.23</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,872.58	4,872.58
Other equity	19,403.60	19,002.00
<b>Equity attributable to equity holders of the parent</b>	<b>24,276.18</b>	<b>23,874.58</b>
Non controlling interest	0.06	0.03
<b>Total equity</b>	<b>24,276.24</b>	<b>23,874.61</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	4,010.18	3,560.06
Other financial liabilities	352.55	294.95
Deferred tax liabilities (net)	1,041.69	1,010.09
	<b>5,404.42</b>	<b>4,865.10</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	5,725.09	7,075.20
Lease Liabilities	333.79	247.18
Trade payables		
-total outstanding due of micro enterprises and small enterprises	68.49	6.31
-total outstanding due of creditors other than micro enterprises and small enterprises	4,703.77	6,231.78
Other financial liabilities	921.67	1,077.72
Other current liabilities	1,232.28	1,224.65
Provisions	57.26	79.68
Current Tax Liabilities (net)	12.63	-
	<b>13,054.98</b>	<b>15,942.52</b>
<b>TOTAL LIABILITIES</b>	<b>18,459.40</b>	<b>20,807.62</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>42,735.64</b>	<b>44,682.23</b>



### C. Consolidated Cash Flow Statement

	Half Year ended 30.09.2024 Rs. in lakhs (Unaudited)	Half Year ended 30.09.2023 Rs. in lakhs (Unaudited)
<b>Cash flow from operating activities</b>		
<b>Profit before tax</b>	<b>419.73</b>	<b>562.88</b>
Depreciation and amortisation expense	994.37	811.11
Government Incentive	(5.12)	(4.05)
Interest on Lease deposits	(3.61)	(1.69)
(Gain) on sale of property, plant and equipment (net)	(3.01)	(45.38)
Unrealized Foreign Exchange (Gain)	(78.40)	(69.13)
Provision for employee benefits	(26.94)	(32.57)
Dividend income on investments	(0.75)	(0.60)
Interest income	(2.11)	(2.82)
Employee compensation cost (ESOP costs)	65.39	-
Finance costs	574.60	295.11
<b>Operating profit before working capital changes</b>	<b>1,934.15</b>	<b>1,512.86</b>
Movement in working capital :		
(Decrease) in trade and other payables	(1,416.28)	(985.80)
(Increase)/decrease in inventories	1,333.71	(1,236.93)
Decrease in trade and other receivables	1,857.58	2,408.76
<b>Net Cash generated from operations</b>	<b>3,709.16</b>	<b>1,698.89</b>
Direct taxes paid (net of refunds)	(28.98)	617.28
<b>Net cash from operating activities (A)</b>	<b>3,680.18</b>	<b>2,316.17</b>
<b>Cash flow from investing activities</b>		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(2,459.70)	(3,237.24)
Sale proceeds of property, plant and equipment and intangibles	3.72	46.49
Deposits placed with bank (having original maturity of more than three months)	(34.50)	(150.00)
Maturity of bank deposits (having original maturity of more than three months)	17.50	32.82
Interest received	0.40	1.48
Dividend received	0.75	0.60
<b>Net cash (used in) investing activities (B)</b>	<b>(2,471.83)</b>	<b>(3,305.85)</b>
<b>Cash flow from financing activities</b>		
Deemed equity contribution from shareholder (net)	-	2,140.24
Proceeds from long term borrowings	1,403.86	2,113.55
(Repayment) of long term borrowings	(690.04)	(650.66)
(Repayment) of short term borrowings (net)	(1,545.32)	(1,334.94)
(Repayment) of principal portion of lease obligations	(189.94)	(83.25)
Finance costs paid	(644.25)	(369.64)
Changes in unclaimed dividend bank balances	0.04	0.15
Dividends paid on equity shares (including unclaimed)	(0.04)	(0.15)
<b>Net cash generated from financing activities (C)</b>	<b>(1,665.69)</b>	<b>1,815.30</b>
<b>Effects of exchange rate changes on cash and cash equivalents (D)</b>	<b>4.82</b>	<b>9.46</b>
Net increase in cash and cash equivalents (A+B+C+D)	(452.52)	835.08
Opening cash and cash equivalents	960.02	642.05
<b>Closing cash and cash equivalents</b>	<b>507.50</b>	<b>1,477.13</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	16.26	20.32
Balances with banks in:		
- Current accounts	491.24	1,456.81
<b>Total Cash and cash equivalents</b>	<b>507.50</b>	<b>1,477.13</b>

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cashflow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows



**Notes :**

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09 November 2024. There are no qualifications in the limited review report issued for the quarter & half year ended 30 September 2024.
- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company and its subsidiaries are principally engaged in a single business segment which is "pharmaceuticals".

**ANWAR  
SIRAJ DAUD**

Digitally signed by ANWAR SIRAJ DAUD  
DN: cn=AN, postalCode=440002, o=MAHARASHTRA,  
street=NAGPUR, postalCode=440002, st=MAHARASHTRA,  
serialNumber=433422b11b06d1f85c8f8e73d1bc5d5da31  
5d6c1087132ac29e0d95c  
serialNumber=991820212911594366,  
2.5.4.20=91c258f03d2eb12217d9e4d11e7d67d99b0d  
737676c622b6c2785d72, email=ANWAR.DAUD@MILAB.N,  
cn=ANWAR SIRAJ DAUD  
Date: 2024.11.09 16:19:52 +05'30'

**Place: Nagpur  
Date: 09 November 2024**

**Anwar S. Daud  
Managing Director**



---

**Walker Chandiook & Co LLP**

16th Floor, Tower III,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2699  
F +91 22 6626 2601

## **Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

### **To the Board of Directors of ZIM Laboratories Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **ZIM Laboratories Limited** ('the Company') for the quarter ended **30 September 2024** and the year to date results for the period 01 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**ZIM Laboratories Limited**

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

**KHUSHROO** Digitally signed by  
**B PANTHAKY** KHUSHROO B PANTHAKY  
Date: 2024.11.09 16:32:13  
+05'30'

**Khushroo B. Panthaky**

Partner

Membership No:042423

**UDIN:24042423BKCXMK1021**

Place: Mumbai

Date: 09 November 2024



**ZIM Laboratories Limited**

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India  
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

**A. STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30 SEPTEMBER 2024**

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income</b>						
	a) Revenue from operations	8,972.13	8,200.41	8,525.95	17,172.54	15,226.66	36,547.32
	b) Other income	132.15	98.03	142.14	230.18	205.38	469.10
	<b>Total income</b>	<b>9,104.28</b>	<b>8,298.44</b>	<b>8,668.09</b>	<b>17,402.72</b>	<b>15,432.04</b>	<b>37,016.42</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	3,551.84	3,100.93	4,096.35	6,652.77	7,270.36	17,769.83
	b) Purchases of stock-in-trade	313.84	265.74	204.04	579.58	267.13	779.61
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	287.20	314.37	(308.40)	601.57	(434.05)	(1,405.32)
	d) Employee benefits	1,443.76	1,348.05	1,224.49	2,791.81	2,436.89	5,081.03
	e) Finance costs	288.61	285.75	121.69	574.36	295.11	692.44
	f) Depreciation and amortisation	497.34	491.60	371.69	988.94	737.65	1,482.93
	g) Other expenses	2,536.53	2,383.58	2,413.26	4,920.11	4,336.24	10,311.93
	<b>Total expenses</b>	<b>8,919.12</b>	<b>8,190.02</b>	<b>8,123.12</b>	<b>17,109.14</b>	<b>14,909.33</b>	<b>34,712.45</b>
3	<b>Profit before tax (1-2)</b>	<b>185.16</b>	<b>108.42</b>	<b>544.97</b>	<b>293.58</b>	<b>522.71</b>	<b>2,303.97</b>
4	<b>Tax expense</b>						
	Current Tax	23.62	21.00	81.85	44.62	81.85	82.96
	Deferred Tax	39.97	11.52	45.33	51.49	37.37	545.46
	<b>Total tax expense</b>	<b>63.59</b>	<b>32.52</b>	<b>127.18</b>	<b>96.11</b>	<b>119.22</b>	<b>628.42</b>
5	<b>Profit after tax (3-4)</b>	<b>121.57</b>	<b>75.90</b>	<b>417.79</b>	<b>197.47</b>	<b>403.49</b>	<b>1,675.55</b>
6	<b>Other comprehensive income - profit/(loss)</b>						
	a) Items that will not be reclassified to profit or loss	(13.47)	(13.47)	(16.29)	(26.94)	(32.57)	(53.88)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	3.92	3.92	4.74	7.84	9.48	15.69
	<b>Other comprehensive income (net of tax) - profit/(loss)</b>	<b>(9.55)</b>	<b>(9.55)</b>	<b>(11.55)</b>	<b>(19.10)</b>	<b>(23.09)</b>	<b>(38.19)</b>
7	<b>Total comprehensive income (5+6)</b>	<b>112.02</b>	<b>66.35</b>	<b>406.24</b>	<b>178.37</b>	<b>380.40</b>	<b>1,637.36</b>
8	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
9	Other equity (revaluation reserve : Rs. Nil)						18,322.84
10	Earnings per share (face value of Rs. 10/- each) (not annualised for quarters) ( Rs. )						
	Basic	0.25	0.16	0.86	0.41	0.83	3.44
	Diluted	0.25	0.16	0.86	0.41	0.83	3.44



**B. Standalone Balance Sheet**

	As at 30.09.2024 Rs. in lakhs (Unaudited)	As at 31.03.2024 Rs. in lakhs (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	16,439.76	15,691.89
Capital work-in-progress	3,334.70	2,351.60
Intangible assets	299.68	357.43
Intangible assets under development	2,082.24	1,673.11
Financial Assets		
Investment in subsidiaries	972.15	817.81
Other Investments	5.15	5.15
Other financial assets	85.81	78.30
Non-current tax assets (net)	356.73	367.43
Other non-current assets	504.69	1,135.99
	<b>24,080.91</b>	<b>22,478.71</b>
<b>Current assets</b>		
Inventories	6,792.58	8,126.29
Financial Assets		
Trade receivables	7,266.91	10,009.25
Cash and cash equivalents	25.94	17.35
Bank balances other than cash and cash equivalents	64.95	57.99
Other financial assets	20.07	31.85
Other current assets	3,575.43	3,528.59
	<b>17,745.88</b>	<b>21,771.32</b>
<b>TOTAL ASSETS</b>	<b>41,826.79</b>	<b>44,250.03</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,872.58	4,872.58
Other equity (Refer Note 5)	18,566.60	18,322.84
	<b>23,439.18</b>	<b>23,195.42</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	4,010.18	3,560.06
Lease Liabilities	352.55	294.95
Deferred tax liabilities (net)	1,053.74	1,010.09
	<b>5,416.47</b>	<b>4,865.10</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	5,725.09	7,075.20
Lease Liabilities	333.79	247.18
Trade payables		
-total outstanding due of micro enterprises and small enterprises	68.49	6.31
-total outstanding due of creditors other than micro enterprises and small enterprises	4,749.21	6,260.15
Other financial liabilities	837.92	1,063.51
Other current liabilities	1,187.25	1,457.48
Provisions	57.26	79.68
Current Tax Liabilities (net)	12.13	-
	<b>12,971.14</b>	<b>16,189.51</b>
<b>TOTAL LIABILITIES</b>	<b>18,387.61</b>	<b>21,054.61</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>41,826.79</b>	<b>44,250.03</b>



### C. Standalone Cash Flow Statement

	Half year ended 30.09.2024	Half year ended 30.09.2023
	Rs. in lakhs	Rs. in lakhs
	(Unaudited)	(Unaudited)
<b>Cash flow from operating activities</b>		
<b>Profit before tax</b>	<b>293.58</b>	<b>522.71</b>
Depreciation and amortisation expense	988.94	737.65
Government Incentive	(5.12)	(4.05)
Interest on Lease deposits	(3.61)	(1.69)
Loss on sale of property, plant and equipment (net)	0.71	1.11
Unrealized foreign exchange (Gain)	(78.40)	(69.13)
Provision for employee benefits	(26.94)	(32.57)
Dividend income on investments	(0.75)	(0.60)
Interest income	(1.90)	(2.82)
Employee compensation cost (ESOP costs)	19.03	-
Finance costs	574.36	295.11
<b>Operating profit before working capital changes</b>	<b>1,759.90</b>	<b>1,445.72</b>
Movement in working capital :		
(Decrease)in trade and other payables	(1,769.13)	(946.36)
(Increase)/decrease in inventories	1,333.71	(1,236.93)
Decrease in trade and other receivables	2,732.15	1,524.37
<b>Net Cash generated from operations</b>	<b>4,056.63</b>	<b>786.80</b>
Direct taxes paid (net of refunds)	(21.78)	624.56
<b>Net cash from operating activities (A)</b>	<b>4,034.85</b>	<b>1,411.36</b>
<b>Cash flow from investing activities</b>		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(2,245.77)	(3,216.00)
Investment in subsidiary	(107.98)	-
Deposits placed with bank (having original maturity of more than three months)	(25.50)	(150.00)
Maturity of bank deposits (having original maturity of more than three months)	17.50	61.08
Interest received	0.19	1.48
Dividend received	0.75	0.60
<b>Net cash (used in) investing activities (B)</b>	<b>(2,360.81)</b>	<b>(3,302.84)</b>
<b>Cash flow from financing activities</b>		
Deemed equity contribution from shareholder (net)	-	2,140.24
Proceeds from long term borrowings	1,403.86	2,113.55
(Repayment) of long term borrowings	(690.05)	(650.66)
(Repayment) of short term borrowings	(1,545.32)	(1,334.94)
(Repayment) of lease obligations	(189.94)	(83.25)
Finance costs paid	(644.00)	(369.64)
Changes in unclaimed dividend bank balances	0.04	0.15
Dividends paid on equity shares (unclaimed)	(0.04)	(0.15)
<b>Net cash generated from financing activities (C)</b>	<b>(1,665.45)</b>	<b>1,815.30</b>
Net (decrease)/increase in cash and cash equivalents (A+B+C)	8.59	(76.18)
Opening cash and cash equivalents	17.35	110.98
<b>Closing cash and cash equivalents</b>	<b>25.94</b>	<b>34.80</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	16.26	20.32
Balances with banks in:		
- Current accounts	9.68	14.48
<b>Total Cash and cash equivalents</b>	<b>25.94</b>	<b>34.80</b>

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cash flow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows



**Notes (A to C):**

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09 November 2024. There are no qualifications in the limited review report issued for the quarter and half year ended 30 September 2024.
- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company is principally engaged in a single business segment which is "pharmaceuticals".

**Place: Nagpur**  
**Date: 09 November 2024**



**ANWAR**  
**SIRAJ DAUD**

**Anwar S. Daud**  
**Managing Director**

Digitally signed by ANWAR SIRAJ DAUD  
DN: cn=ANWAR SIRAJ DAUD, o=ANWAR SIRAJ DAUD, ou=ANWAR SIRAJ DAUD, email=ANWAR.SIRAJ.DAUD@ANWAR.SIRAJ.DAUD.COM, c=IN  
c=IN, o=ANWAR SIRAJ DAUD, ou=ANWAR SIRAJ DAUD, email=ANWAR.SIRAJ.DAUD@ANWAR.SIRAJ.DAUD.COM, c=IN  
ANWAR SIRAJ DAUD  
25.4.2025 11:09:16 AM  
ANWAR SIRAJ DAUD  
Date: 2024.11.09 16:20:02 +05'30'